Compassionate Use of Vonsetamig
NCT07780110 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-08-21
Summary
Provide Compassionate Use of Vonsetamig
Conditions
- Plasma Cell Mediated
- Antibody Mediated
Interventions
- DRUG
-
Vonsetamig
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Third Party Viral Specific T-cells (VSTs)
NCT02532452 ·Status: RECRUITING ·Phase: PHASE2
-
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates
NCT00722722 ·Status: COMPLETED ·Phase: PHASE2
-
Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)
NCT02314403 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate Effects and Safety of Pre-load Myfortic® in Transplant Patients
NCT01336296 ·Status: COMPLETED ·Phase: PHASE4
-
Withdrawal of Immunosuppression in Recipients of Face and Extremity Transplants
NCT01853111 ·Status: COMPLETED ·Phase: PHASE1
-
Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation
NCT02351427 ·Status: UNKNOWN ·Phase: PHASE3
-
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
NCT07332338 ·Status: AVAILABLE
-
Safety and Efficacy of BiTE in Desensitization Therapy for Highly Sensitized Kidney Transplant Candidates With cPRA ≥ 90%
NCT07689149 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Study of SG301 for Renal AMR After Transplantation
NCT07764627 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
The Efficacy and Safety of Desensitation Regimen for Patients With High Titers of Anti-HLA Antibodies Prior to Allo-HSCT
NCT06362967 ·Status: RECRUITING ·Phase: PHASE2
-
Companion for CAR-T Web App During Chimeric Antigen Receptor T-cell Therapy
NCT05362331 ·Status: WITHDRAWN ·Phase: NA
-
Donor-Derived Viral Specific T-cells (VSTs)
NCT02048332 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
NCT01713400 ·Status: COMPLETED ·Phase: PHASE2
-
(TNX-1500) in Kidney Transplant Recipients
NCT07204080 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PERSPECTIVE)
NCT04803058 ·Status: TERMINATED ·Phase: PHASE2
-
Expanded Access for ATB200/AT2221 for the Treatment of Pompe Disease
NCT03865836 ·Status: AVAILABLE
-
BK With VST for Kidney Transplant Patients
NCT05042076 ·Status: COMPLETED ·Phase: PHASE1
-
Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD
NCT02511782 ·Status: COMPLETED ·Phase: NA
-
Expansion of Virus-Specific Lymphocytes for Cell Therapy
NCT06011486 ·Status: RECRUITING ·Phase: PHASE1
-
Alternate Donor Study of Pre-Emptive Cellular Therapy
NCT01220895 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
NCT07693881 ·Status: RECRUITING ·Phase: NA
-
Virus-specific Activated T Lymphocytes From a Donor in Hematopoietic Progenitor Transplanted Patients
NCT04018261 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis
NCT01324908 ·Status: TERMINATED ·Phase: NA
-
Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation
NCT01769443 ·Status: TERMINATED ·Phase: PHASE2
-
BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)
NCT05156710 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2